IP Library Granted Patent US 7,750,000
Granted Patent B2
US 7,750,000 · App. 11/514,308 · Granted Jul 6, 2010

Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments

Assignee: Bayer Schering Pharma AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,750,000
App. No.
11/514,308
Granted
Jul 6, 2010
Kind
B2
Abstract

The invention relates to novel inhibitors of kinases, and pharmaceutical compositions comprising them. The inhibitors are substituted imidazo[1,2b]pyridazines.

Claims (47)

1. A compound selected from the group consisting of:

(3-phenylimidazo[1,2b]pyridazin-6-yl)-(3-pyrrolidin-1-ylpropyl)amine

(3-morpholin-4-ylpropyl)-(3-phenylimidazo[1,2b]pyridazin-6-yl)amine

(3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl)-(3-pyrrolidin-1-ylpropyl)amine

(3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl)-(3-morpholin-4-ylpropyl)amine

[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2b]pyridazin-6-yl]pyridin-3-ylmethylamine

(3-phenylimidazo[1,2b]pyridazin-6-yl)pyridin-3-ylmethylamine

(3-imidazol-1-ylpropyl)-(3-phenylimidazo[1,2b]pyridazin-6-yl)amine

(4-fluorobenzyl)-(3-phenylimidazo[1,2b]pyridazin-6-yl)amine

cyclohexylmethyl-(3-phenylimidazo[1,2-b]pyridazin-6-yl)amine

(2,4-difluorobenzyl)-(3-phenylimidazo[1,2b]pyridazin-6-yl)amine

[3-(5-methyl-1H-pyrazol-4-yl)propyl]-(3-phenylimidazo[1,2-b]pyridazin-6-yl)amine

1-[2-(3-phenylimidazo[1,2-b]pyridazin-6-ylamino)ethyl]imidazolidin-2-one

(2-morpholin-4-ylethyl))-(3-phenylimidazo[1,2-b]pyridazin-6-yl)amine

N 1 ,N 1 -diethyl-N 4 -(3-phenylimidazo[1,2-b]pyridazin-6-yl)pentane-1,4-diamine

N,N-diethyl-N′-(3-phenylimidazo[1,2-b]pyridazin-6-yl)propane-1,3-diamine

(3-phenylimidazo[1,2-b]pyridazin-6-yl)-(2-pyrrolidin-1-ylethyl)amine

[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]pyridin-3ylmethylamine

[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-(3-imidazol-1-ylpropyl)amine

3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl)-(4-fluorobenzyl)amine

3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl)cyclohexylmethylamine

3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl)-(2,4-difluorobenzyl)amine

1-{2-[3-(3-phenyl)imidazo[1,2-b]pyridazin-6-ylamino]ethyl}imidazolidin-2-one

N 4 -[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]N 1 ,N 1 -diethylpentane-1,4-diamine

N′-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N,N-diethylpropane-1,3-diamine

[3-(3-chlorophenyl)imidazo[1,2b]pyridazin-6-yl]-(2-pyrrolidin-1-ylethyl)amine

(3-imidazol-1-ylpropyl)-[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl]amine

(4-fluorobenzyl)-[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl]amine

cyclohexylmethyl-[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl]amine

(2,4-difluorobenzyl)-[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl]amine

[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2b]pyridazin-6-yl]-[5-methyl-1H-pyrazol-4-yl)propyl]amine

1-{2-[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-ylamino]ethyl}imidazolidin-2-one

(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)-(2-morpholin-4-ylethyl)amine

N 1 ,N 1 -diethyl-N 4 -[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2b]pyridazin-6-yl]pentane-1,4-diamine

N,N-diethyl-N′-[3-(1-methyl-1H-1-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl]propane-1,3-diamine

[3-(1-methyl-1H-pyrazol-4-yl)imidazo [1,2-b]pyridazin-6-yl-(2-pyrrolidin-1-ylethyl)amine

pyridin-3-ylmethyl-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl)amine

(4-fluorobenzyl)-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl)amine

cyclohexylmethyl-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl)amine

(2,4-difluorobenzyl)-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl)amine

[3-(5-methyl-1H-pyrazol-4-yl)propyl)-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl)amine

1-[2-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-ylamino)ethyl]imidazolidin-2-one

(2-morpholin-4-ylethyl)-(3-thiophen-3-ylimidazO[1,2-b]pyridazin-6-yl)amine

N 1 ,N 1 -diethyl-N 4 -[3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl]pentane-1,4-diamine

N,N-diethyl-N′-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl]propane-1,3-diamine and

(2-pyrrolidin-1-ylethyl)-(3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-yl)amine.

2. A pharmaceutical composition, comprising a compound as claimed in claim 1 and at least one pharmaceutical excipient.

Assignments (4)
CHANGE OF NAME Recorded May 17, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030437/0387 →
CHANGE OF NAME Recorded Jan 22, 2013
From: SCHERING AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029666/0244 →
CHANGE OF NAME Recorded Jan 22, 2013
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029666/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2006
From: PRIEN, OLAF; INCE, STUART JAMES; EIS, KNUT; HUWE, CHRISTOPH; LUCKING, ULRICH; JAUTELAT, ROLF; ZUGEL, ULRICH; GUNTHER, JUDITH; BADER, BENJAMIN; HUSEMANN, MANFRED; SCHUCK, KARINA
To: SCHERING AG
Reel/Frame 018712/0844 →
Priority Claims (1)
DE 10 2005 042 742 · Sep 2, 2005 · national
Continuity (2)
Provisional Application 6071333300 · Sep 2, 2005
Related Publication 20070093490A1 · Apr 26, 2007